Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Cash & Equivalents (2020 - 2026)

MDxHealth has reported Cash & Equivalents over the past 7 years, most recently at $29.0 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 37.96% year-over-year to $29.0 million; the TTM value through Mar 2026 reached $29.0 million, down 37.96%, while the annual FY2025 figure was $29.0 million, 37.96% down from the prior year.
  • Cash & Equivalents was $29.0 million for Q1 2026 at MDxHealth, roughly flat from $29.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $46.8 million in Q4 2024 and bottomed at $15.5 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $29.0 million (2025), against an average of $31.6 million.
  • Year-over-year, Cash & Equivalents tumbled 73.5% in 2022 and then soared 109.11% in 2024.
  • Over 5 years, Cash & Equivalents stood at $15.5 million in 2022, then soared by 44.36% to $22.4 million in 2023, then soared by 109.11% to $46.8 million in 2024, then plummeted by 37.96% to $29.0 million in 2025, then changed by 0.0% to $29.0 million in 2026.
  • The last three reported values for Cash & Equivalents were $29.0 million (Q1 2026), $29.0 million (Q4 2025), and $46.8 million (Q1 2025) per Business Quant data.